case_images: PMC2828414_01
case_images: PMC2828414_02
case_images: Metabolic response of one patient treated with imatinib mesylate. Comparison of FDG PET imaging pre- (a, b) and post- (c, d) three months of therapy.
case_images: 1471-2407-10-22-1.jpg
case_images: PMC2828414_02_1471-2407-10-22-1.jpg
case_images: F1
case_images: The FDG PET scan images documenting the metabolic response of one patient are illustrated in Figure 1.
case_images: Local progression-free survival of all surgically treated chordoma patients.
case_images: 1471-2407-10-22-2.jpg
case_images: PMC2828414_02_1471-2407-10-22-2.jpg
case_images: F2
case_images: Overall survival of the entire series of 25 chordoma patients.
case_images: 1471-2407-10-22-3.jpg
case_images: PMC2828414_02_1471-2407-10-22-3.jpg
case_images: F3
case_images: The 5-year and 10-year survival rate of the entire series was 76.7% and 59.7%, respectively (Figure 3).